安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Homepage - GRAIL
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable
- Multi-cancer early detection - GRAIL
GRAIL uses advanced machine learning algorithms and pattern recognition to “read” methylation patterns Using these two principles, the Galleri test has three scientific steps: Extract and sequence the DNA fragments from the blood to “read” the methylation patterns (assay)
- Press Releases - GRAIL
GRAIL Presents New Data Demonstrating That Methylation Assay Detects Residual Hematologic Cancer After Treatment at American Association for Cancer Research Annual Meeting 2023
- Clinical Studies - GRAIL
GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Our clinical study program We are committed to the utmost scientific rigor and have enrolled over 300,000 participants in a clinical study program to demonstrate broad applicability of our multi-cancer early detection
- Careers - GRAIL
Everything we do is guided by our mission to detect cancer early, when it can be cured We have a group of people at GRAIL whose talent, commitment, and creativity are unmatched And as we grow, we’re looking for people who will increase the impact we can make on the world
- Diagnostic Aid for Cancer - GRAIL
GRAIL Updates; The Cancer SIGNAL Podcast; Media Resources; Investor Relations; Galleri Test; Careers; Get in touch; Search Diagnostic Aid for Cancer We are developing our diagnostic aid for cancer (“DAC”) test to accelerate diagnostic resolution for patients with non-specific signs and symptoms, but with a clinical suspicion of cancer
- GRAIL and Quest Diagnostics Provide GRAIL’s Galleri® Multi-Cancer Early . . .
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
- GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring
|
|
|